Autel to Showcase Breakthrough EV Charging Innovations at ICNC23
29.8.2023 12:21:00 EEST | Business Wire | Press release
Autel Energy, a leading provider of innovative EV charging solutions, is pleased to announce its participation in the highly-anticipated Intercharge Network Conference 2023 (ICNC23) to be held on August 29-31, 2023, in Berlin. Ting Cai, CEO of Autel Europe, is set to captivate the audience with an insightful speech on the future of EV charging. Autel's hallmark innovation, the MaxiCharger DC Compact, will take center stage as it makes a live demonstration at the Plug&Charge Showcase Zone to showcase its seamless charging process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230828771064/en/
Complete MaxiCharger Lineup Unveiled at ICNC23 and IAA MOBILITY 2023 (Graphic: Business Wire)
ICNC23 is renowned for bringing together top industry professionals, experts, and stakeholders in the electric vehicle charging infrastructure domain. Ting Cai’s speech and Autel’s charging capabilities of its products will provide attendees with an exclusive opportunity to experience first-hand the cutting-edge technology that Autel Energy has brought to the market.
Autel MaxiCharger series offer a revolutionary charging solution that has transformed the charging experience for electric vehicle owners. With its high-speed charging capabilities, intuitive user interface, and compatibility with various electric vehicle models, Autel has earned its reputation as an indispensable tool for EV owners. Notably, Autel Energy has been officially checked and validated by Hubject, making its way into the Plug&Charge ecosystem. At ICNC23, Autel will bring its MaxiCharger DC Compact to demonstrate the charging process at the Plug&Charge Showcase Zone, which will impeccably showcase its exceptional features, emphasizing its role in providing a seamless and efficient charging process for electric vehicles.
Following the ICNC23, Autel Energy is excited to continue its engagement with the electric vehicle community at IAA MOBILITY 2023 (International Motor Show Germany) to take place on September 5-10, 2023, in Munich. During this period, Autel will embark on a roadshow, with its event vehicles journeying from ICNC in Berlin all the way to IAA MOBILITY in Munich and ultimately welcoming visitors at booth C2 A31.
"We are delighted to be part of ICNC23 and IAA MOBILITY 2023, where we can showcase the capabilities of Autel’s EV chargers and its seamless integration with various EV models," said Ting Cai, CEO of Autel Europe. "As the EV market continues to grow, Autel Energy remains committed to delivering cutting-edge charging solutions that enhance the driving experience for EV owners worldwide."
Visitors attending ICNC23 and IAA MOBILITY will have the exclusive opportunity to explore the charging process of the demonstration EV by Autel Energy's comprehensive array of EV charging products. Autel Energy's team of experts will be available at the event to engage with visitors, share insights, and discuss the transformative potential of their cutting-edge charging solutions.
For more information about Autel Energy and its EV charging solutions, please visit: https://autelenergy.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230828771064/en/
Contact information
Jiaqi Liu
Email:jiaqi.liu@autel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom